SBTX vs. BVXP, CIR, 4BB, AVCT, TILS, VSN, OBI, SCLP, MPH, and HVO
Should you be buying SkinBioTherapeutics stock or one of its competitors? The main competitors of SkinBioTherapeutics include Bioventix (BVXP), Circassia Group (CIR), 4basebio (4BB), Avacta Group (AVCT), Tiziana Life Sciences (TILS), Verseon (VSN), Ondine Biomedical (OBI), Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), and hVIVO (HVO). These companies are all part of the "biotechnology" industry.
SkinBioTherapeutics vs. Its Competitors
SkinBioTherapeutics (LON:SBTX) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.
SkinBioTherapeutics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, Bioventix has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.
In the previous week, Bioventix had 1 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 1 mentions for Bioventix and 0 mentions for SkinBioTherapeutics. SkinBioTherapeutics' average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.
Bioventix has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.
16.6% of SkinBioTherapeutics shares are held by institutional investors. Comparatively, 62.3% of Bioventix shares are held by institutional investors. 20.4% of SkinBioTherapeutics shares are held by insiders. Comparatively, 8.0% of Bioventix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Bioventix has a net margin of 59.51% compared to SkinBioTherapeutics' net margin of -237.95%. Bioventix's return on equity of 69.09% beat SkinBioTherapeutics' return on equity.
Summary
Bioventix beats SkinBioTherapeutics on 9 of the 12 factors compared between the two stocks.
Get SkinBioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SkinBioTherapeutics Competitors List
Related Companies and Tools
This page (LON:SBTX) was last updated on 7/6/2025 by MarketBeat.com Staff
Free SBTX Stock Alerts